The Jack Watters debate - tackling antimicrobial resistance in an ageing society, took place on the 16th November 2016 at the Old Operating Theatre Museum in London. This event was dedicated to a long term supporter of the ILC and a pioneer in championing the health and well-being of ageing people, Dr. Jack Watters. The debate was chaired by Baroness Sally Greengross (Chief Executive, ILC-UK) and saw the participation of the following speakers: - Professor David Salisbury CB, Associate Fellow, Centre on Global Health Security Chatham House - Matthew Edwards, Head of Mortality and Longevity, Towers Watson - Michelle Bresnahan, Founder, A Life for a Cure - Dr Gina Radford, Deputy Chief Medical Officer http://www.ilcuk.org.uk/index.php/events/tackling_antimicrobial_resistance_in_an_ageing_society

1. The Dr Jack Watters debate:
Tackling antimicrobial resistance in an
ageing society
Wednesday, 16th November 2016
This event is kindly supported by Pfizer
#futureofAMR

2. Welcome
Baroness Sally Greengross
Chief Executive
ILC-UK
This event is kindly supported by Pfizer
#futureofAMR

3. Welcome
Paula DeCola
Senior Director, Global Patient Affairs
Pfizer
This event is kindly supported by Pfizer
#futureofAMR

4. Professor David Salisbury
Associate Fellow
Centre for Global Health Security
Chatham House
This event is kindly supported by Pfizer
#futureofAMR

5. Antimicrobial resistance in an
ageing population
Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci
Associate Fellow, Centre on Global Health Security,
Royal Institute for International Affairs, Chatham House, London.

6. Debate: The role of vaccines and
antimicrobial resistance in an ageing
population.
There is no debate!

7. Vaccines that we already use that are relevant to an
ageing society.
Rotavirus vaccine for young children.
Pneumococcal conjugate vaccine for young children.
Meningococcal vaccines (C, B, Y, W)
Haemophilus influenza b for young children.
Influenza vaccine for children and risk groups.
Varicella zoster vaccine

8. Haemophilus influenzae type b – Laboratory Reports
England 1990 - 2012
Very successful control of
Invasive Hib Disease

9. Neisseria meningitidis type C (MenC). E&W;
1998 – 2009.
0
100
200
300
400
500
600
700
800
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Year
NumberofMenCcases
Under 20 years old
Over 20 years old
Introduction of the Meningococcal C vaccine
Source HPA

10. Impact of PCV 7 and 13
Cases in children >5 years
0
50
100
150
200
250
300
350
400
450
500
1997/8 1998/9 1999/0 2000/1 2001/2 2002/3 2003/4 2004/5 2005/6 2006/7 2007/8 2008/9
Epidemiological year
NumberofCases
4, 6B, 9V, 14, 18C, 19F and 23F serotypes contained in Prevenar and Prevenar 13
Prevenar introduced into the routine
childhood immunisation schedule in
2006
Source HPA

12. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/503291/Norovirus_u
pdate_2016_week_06.pdf

13. Vaccines that we may use that are relevant to an
ageing society.
RSV vaccine for children and older ages.
Staph. aureus
C. difficile
E. coli
Norovirus (children, risk groups, older individuals)
Pseudomonas
Klebsiella
Alzheimer’s
Diabetes
Cancer vaccines

14. Debate: The role of vaccines in
antimicrobial resistance in an ageing
population
Why have vaccines not received a
higher profile?

15. Matthew Edwards
Head of Mortality and Longevity
Willis Towers Watson
This event is kindly supported by Pfizer
#futureofAMR

16. Michelle Bresnahan
Co-Founder
A Life for a Cure
This event is kindly supported by Pfizer
#futureofAMR

17. Panel Discussion
Michelle Bresnahan
Co-Founder
A Life for a Cure
This event is kindly supported by Pfizer
#futureofAMR
Prof David Salisbury
Associate Fellow, Centre for Global
Health Security
Chatham House
Dr Gina Radford
Deputy Chief Medical Officer

18. Close
Baroness Sally Greengross
Chief Executive
ILC-UK
This event is kindly supported by Pfizer
#futureofAMR

19. The Dr Jack Watters debate:
Tackling antimicrobial resistance in an
ageing society
Wednesday, 16th November 2016
This event is kindly supported by Pfizer
#futureofAMR